( SEVAMED 2001)

(Diagnosis, Diagnostics, Immunodiagnosis, Immunodiagnostics, Pathogenesis, Vaccines & Drugs)

Click here for Abstract

Back To Content Page

1318.      Joshi AB.  Singhasivanon P.  Khusmith S.  Fungladda W.  Nandy A. Evaluation of  direct agglutination test (DAT) as an immunodiagnostic tool for diagnosis of visceral  leishmaniasis in Nepal.  Southeast Asian Journal of Tropical Medicine & Public  Health.  30(3):583-5, 1999 Sep.

1737. Corral RS.  Petray PB. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. Vaccine.  19(2-3):234-42, 2000 Sep

1738. Handman E.  Noormohammadi AH.  Curtis JM.  Baldwin T.  Sjolander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine.  18(26):3011-7, 2000 Jul 1.

1739. Hu XS.  Yang WT.  Lu HG.  Yan HP.  Cheng JP.  Ma Y.  Jin BQ.  Zhang T.Sequencing a specific kinetoplast DNA fragment of Leishmania donovani for polymerase chain reaction  amplification  in  diagnosis  of  leishmaniasis  in  bone marrow and blood samples. Journal of Parasitology.  86(4):822-6, 2000 Aug.

1740. Kamau SW.  Hurtado M.  Muller-Doblies UU.  Grimm F.  Nunez R. Flow cytometric assessment  of  allopurinol  susceptibility  in  Leishmania  infantum  promastigote. Cytometry.  40(4):353-60, 2000 Aug 1.

1741.   Kaul P.  Malla N.  Kaur S.  Mahajan RC.  Ganguly NK. Evaluation of a 200-kDa amastigote-specific  antigen  of  L. donovani  by  enzyme-linked  immunosorbent assay (ELISA) for the diagnosis of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine & Hygiene. 94(2):173-5, 2000 Mar-Apr.

1742. Llorente S. Gimeno L. Navarro MJ. Moreno S. Rodriguez-Girones M.Therapy of visceral  leishmaniasis  in  renal  transplant  recipients  intolerant  to   pentavalent antimonials.Transplantation.  70(5):800-1, 2000 Sep 15.

1743.   Passos VM. Barreto SM. Romanha AJ. Krettli AU.  Volpini AC.  Lima e Costa MF. American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment.Bulletin of the World Health Organization.  78(8):968-74, 2000.

1744. Rais S.  Perianin A.  Lenoir M.  Sadak A.  Rivollet D.  Paul M.  Deniau M.  Sodium stibogluconate ( Pentostam )  potentiates  oxidant  production  in  murine  visceral leishmaniasis and in human blood. Antimicrobial Agents & Chemotherapy.  44(9): 2406-10, 2000 Sep.

1745. Vicandi B. Jimenez-Heffernan JA.  Lopez-Ferrer P.  Ortega L.  Viguer JM.  Cytologic diagnosis of leishmaniasis in HIV infection. A report of eight cases.Acta Cytologica 44(5):835-9, 2000 Sep-Oct.

2199.      Attar ZJ.  Chance ML.  el-Safi S.  Carney J.  Azazy A.  El-Hadi M.  Dourado C.  Hommel M. Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis. Acta Tropica.  78(1):11-6, 2001 Jan 15.

2200.      Babaloo Z.  Kaye PM.  Eslami MB. Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines.  Transactions of the Royal Society of Tropical Medicine & Hygiene.  95(1):85-8, 2001 Jan-Feb.

2201.      Baddini-Caramelli C.  Matayoshi S.  Moura EM.  Araf D.  Santo R.  Voegels R.  Kara-Jose N.  Chronic dacryocystitis in American mucocutaneous leishmaniasis. Ophthalmic Plastic & Reconstructive Surgery.  17(1):48-52, 2001 Jan.

2202.      Bogdan C.  Schonian G.  Banuls AL.  Hide M.  Pratlong F.  Lorenz E.  Rollinghoff M.  Mertens R. Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. [Review] [35 refs]  Clinical Infectious Diseases.  32(2):302-6, 2001 Jan 15.

2203.      Bourreau E.  Prevot G.  Pradinaud R.  Launois P. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12.  Journal of Infectious Diseases.  183(6):953-9, 2001 Mar 15.

2204.      Buchovsky AS.  Campetella O.  Russomando G.  Franco L.  Oddone R.  Candia N.  Luquetti A.  Gonzalez Cappa SM.  Leguizamon MS. trans-sialidase inhibition assay, a highly sensitive and specific diagnostic test for Chagas' disease. Clinical & Diagnostic Laboratory Immunology.  8(1):187-9, 2001 Jan.

2205.      Carrio J.  Riera C.  Gallego M.  Ribera E.  Portus M. In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients. Journal of Antimicrobial Chemotherapy.  47(1):120-1, 2001 Jan.

2206.      Fargnoli MC.  Peris K.  Cerroni L.  Piccolo D.  Chimenti S.  A nodule on the forearm of a patient with Hodgkin disease.  Archives of Dermatology.  137(1):85-90, 2001 Jan.

2207.      Gicheru MM.  Olobo JO.  Anjili CO.  Orago AS.  Modabber F.  Scott P.  Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infection & Immunity.  69(1):245-51, 2001 Jan.

2208.      Hussein MM.  Mooij JM.  Roujouleh HM.  Hamour OA.  Felemban H.  Non-typhoid Salmonella septicemia and visceral leishmaniasis in a renal transplant patient.  Transplantation.  71(3):479-81, 2001 Feb 15.

2209.      Kumar A.  Mittal M.  Prasad S. Treatment of leishmaniasis in pregnancy.  International Journal of Gynaecology & Obstetrics.  72(2):189-90, 2001 Feb.

2210.      Lachaud L.  Chabbert E.  Dubessay P.  Reynes J.  Lamothe J.  Bastien P. Comparison of various sample preparation methods for PCR diagnosis of visceral leishmaniasis using peripheral blood.  Journal of Clinical Microbiology.  39(2):613-7, 2001 Feb.

2211.      Marom D.  Offer I.  Tamary H.  Jaffe CL.  Garty BZ.  Hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis.  Pediatric Hematology & Oncology.  18(1):65-70, 2001 Jan-Feb.

2212.      Pintado V.  Martin-Rabadan P.  Rivera ML.  Moreno S.  Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.  Medicine.  80(1):54-73, 2001 Jan.

2213.      Pizzuto M.  Piazza M.  Senese D.  Scalamogna C.  Calattini S.  Corsico L.  Persico T.  Adriani B.  Magni C.  Guaraldi G.  Gaiera G.  Ludovisi A.  Gramiccia M.  Galli M.  Moroni M.  Corbellino M.  Antinori S. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1.  Journal of Clinical Microbiology.  39(1):357-61, 2001 Jan.

2214.      Probst P.  Stromberg E.  Ghalib HW.  Mozel M.  Badaro R.  Reed SG.  Webb JR. Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning.  Journal of Immunology.  166(1):498-505, 2001 Jan 1.

2215.      Reinecke P.  Gabbart HE.  Strunk W.  Losche CC. Ocular scleromalacia caused by leishmaniasis: a rare cause of scleral perforation. British Journal of Ophthalmology.  85(2):240-1, 2001 Feb.

2216.      Singh RK. Post Kala-azar dermal leishmaniasis.  Journal of the Association of Physicians of India.  49:352, 2001 Mar.

2217.      Soares NM.  Santiago MB.  Pontes deCarvalho LC.  An improved anti-C3/IgG ELISA for quantification of soluble immune complexes.  Journal of Immunological Methods.  249(1-2):199-205, 2001 Mar 1.

2218.      Streit JA.  Recker TJ.  Filho FG.  Beverley SM.  Wilson ME.  Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms.  Journal of Immunology.  166(3):1921-9, 2001 Feb 1.

2219.      Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study.  International Journal of Antimicrobial Agents.  17(1):67-70, 2001 Jan.

2220.      Thakur CP.  Ahmed S.  Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India.  Indian Journal of Medical Research. 113:14-8, 2001 Jan.

2814.      Bottrel RL.  Dutra WO.  Martins FA.  Gontijo B.  Carvalho E.  Barral-Netto M.  Barral A.  Almeida RP.  Mayrink W.  Locksley R.  Gollob KJ. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infection & Immunity.  69(5):3232-9, 2001 May.

2815.      el-Hassan AM.  Zijlstra EE.  Leishmaniasis in Sudan. Mucosal leishmaniasis. Transactions of the Royal Society of Tropical Medicine & Hygiene.  95 Suppl 1:S19-26, 2001 Apr.

2816.      Nylen S.  Mortberg U.  Kovalenko D.  Satti I.  Engstrom K.  Bakhiet M.  Akuffo H. Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors. Clinical & Experimental Immunology.  124(1):43-53, 2001 Apr.

2817.      Palmer RA.  Tran D.  Hepburn NC.  Ashton RE. The management of cutaneous leishmaniasis from Belize. Clinical & Experimental Dermatology.  26(1):16-20, 2001 Jan.

2818.      Zijlstra EE.  el-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine & Hygiene.  95 Suppl 1:S27-58, 2001 Apr.


Click here for Abstract

Back To Content Page